Designing a Long Acting Erythropoietin by Fusing Three Carboxyl-Terminal Peptides of Human Chorionic Gonadotropin Subunit to the N-Terminal and C-Terminal Coding Sequence
Figure 5
In vivo bioactivity of recombinant HuEPO derivatives. ICR mice (/group) received a single IV injection/week (15 mg/kg) for three weeks of EPO-WT, rHuEPO, or EPO-(CTP)3. In addition, mice were treated with 5 μg/kg of rHuEPO three times a week for 3 weeks. Control animals were injected IV with saline. Blood samples were collected three times a week and haematocrit levels were detected. Each point represents the group average of haematocrit (%) ± SE. *, **, and ***.